About jazz pharmaceuticals - JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
JAZZ At a Glance
Jazz Pharmaceuticals Plc
Waterloo Exchange
Dublin, Dublin 4
| Phone | 353-1-634-7800 | Revenue | 4.07B | |
| Industry | Pharmaceuticals: Major | Net Income | 560.12M | |
| Sector | Health Technology | 2024 Sales Growth | 6.122% | |
| Fiscal Year-end | 12 / 2025 | Employees | 2,800 | |
| View SEC Filings |
JAZZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 14.239 |
| Price to Sales Ratio | 1.998 |
| Price to Book Ratio | 1.824 |
| Price to Cash Flow Ratio | 5.82 |
| Enterprise Value to EBITDA | 8.151 |
| Enterprise Value to Sales | 2.778 |
| Total Debt to Enterprise Value | 0.546 |
JAZZ Efficiency
| Revenue/Employee | 1,453,196.429 |
| Income Per Employee | 200,042.857 |
| Receivables Turnover | 5.677 |
| Total Asset Turnover | 0.348 |
JAZZ Liquidity
| Current Ratio | 4.457 |
| Quick Ratio | 3.995 |
| Cash Ratio | 2.882 |
JAZZ Profitability
| Gross Margin | 73.629 |
| Operating Margin | 17.858 |
| Pretax Margin | 11.56 |
| Net Margin | 13.766 |
| Return on Assets | 4.786 |
| Return on Equity | 14.306 |
| Return on Total Capital | 5.459 |
| Return on Invested Capital | 5.858 |
JAZZ Capital Structure
| Total Debt to Total Equity | 150.642 |
| Total Debt to Total Capital | 60.102 |
| Total Debt to Total Assets | 51.339 |
| Long-Term Debt to Equity | 149.524 |
| Long-Term Debt to Total Capital | 59.656 |